Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 19/20 | 1.00 |
| ▸ | CDK4 | P11802 | 17/20 | 1.00 |
| ▸ | CSF1R | P07333 | 16/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.73 |
| ▸ | CDK2 | P24941 | 4/20 | 0.73 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.67 |
| ▸ | CCNK | O75909 | 1/20 | 0.65 |
| ▸ | CDK7 | P50613 | 1/20 | 0.65 |
| ▸ | CDK9 | P50750 | 1/20 | 0.65 |
| ▸ | CCNH | P51946 | 1/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.65 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245694 | 0.94 | CDK6 (1.00) | CDK6CDK4CSF1RCCNA2CDK2 | |
| SCHEMBL21245612 | 0.89 | CDK6 (1.00) | CDK6CDK4CSF1RCCNA2CDK2 | |
| SCHEMBL21267492 | 0.88 | CDK6 (0.80) | CDK6CDK4CSF1RCCNA2CDK2 | |
| SCHEMBL21267889 | 0.87 | CDK6 (0.79) | CDK6CDK4CSF1RCCNA2CDK2 | |
| SCHEMBL21245800 | 0.86 | CDK6 (1.00) | CDK6CDK4CSF1RCCNA2CDK2 | |
| SCHEMBL21267896 | 0.85 | CDK6 (0.75) | CDK6CDK4CSF1RCCNA2CDK2 | |
| SCHEMBL21267840 | 0.85 | CDK6 (0.75) | CDK6CDK4CSF1RCCNA2CDK2 | |
| SCHEMBL21245637 | 0.85 | CDK6 (1.00) | CDK6CDK4CSF1RCCNA2CDK2 | |
| SCHEMBL21267581 | 0.84 | CDK6 (0.78) | CDK6CDK4CSF1RCCNA2CDK2 | |
| SCHEMBL25085604 | 0.84 | CDK6 (0.72) | CDK6CDK4CSF1RCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-112334451-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | CDK6 1/4885CDK4 2/4885CSF1R 3721/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CDK6 2/4885CDK4 1/4885CSF1R 4272/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CDK6 2/4885CDK4 1/4885CSF1R 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.